The quantitative impact of atopic dermatitis on caregivers across multiple life domains

Kim, Richard W.; Barta, Kelly; Begolka, Wendy Smith; Capozza, Korey; Eftekhari, Sanaz; Tullos, Kathryn Z.; Tomaszewski, N.; Snell‐Rood, Claire; Abuabara, Katrina

doi:10.1111/bjd.21855

Cited by 5 publications

(4 citation statements)

References 8 publications

(13 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…After scoring the impact of caring for someone with AD, participants were asked to provide additional comments in free‐text form on how AD caregiving has impacted their life. Quantitative results on caregiving are published in a companion research letter (Kim et al ., this issue of BJD 6 ). Using an iterative, consensus‐building process, we identified themes and developed a codebook with definitions, typical and atypical exemplars, and exclusions 7 .…”

Section: Subdomain Definition Themes Exemplar Quotesmentioning

confidence: 97%

“…The overall impact of caregiving for AD was rated as high or significant by 53% [95% confidence interval (CI) 0Á49-0Á58] of caregivers; this was a similar proportion to patients with AD asked the same question on a parallel survey (51%, 95% CI 0Á48-0Á54; Mann-Whitney P-value = 0Á44). 6 Among subdomains of impact, caregivers ranked sleep, family dynamics and family responsibilities as most impactful: 59% (95% CI 0Á54-0Á64), 46% (95% CI 0Á40-0Á51) and 45% (95% CI 0Á40-0Á50), respectively.…”

mentioning

confidence: 99%

“…Patient responses and qualitative analyses from open-ended caregiver responses are published separately. 5,6 We examined two measures of caregiver impact: (i) an overall impact score in response to the question 'On a scale of 1 to 5 (with 1 being 'no impact' and 5 being 'significant impact'), how much have the person's AD symptoms negatively impacted your own life over the past month? '; and (ii) subdomain impact scores using the same question focused on each of 13 life subdomains (sleep, diet, physical activity, life decisions, family dynamics, family responsibilities, leisure activities, ability to concentrate, stress, self-confidence, work responsibilities, social relationships and intimate relationships).…”

mentioning

confidence: 99%

“…This is likely a multifactorial phenomenon comprised of varying host gene expression profiles, tumour molecular heterogeneity and unique tumour microenvironments. 6 There also exist differences in the anatomical domains of T lymphocytes, with skin-resident T cells being localized and active in the epidermis and high dermis compared with circulating T cells, which are present and functional in the peripheral blood, lymphatics and subdermal soft tissue. 7 Epidermal dysplasia and superficial cSCCs are likely able to evade recognition by circulating T cells, which are probably the group disinhibited by PD-1 inhibitor therapy.…”

mentioning

confidence: 99%

See 3 more Smart Citations

Qualitative analysis of the impact of atopic dermatitis on caregivers

Kim

Barta

Begolka

et al. 2022

British Journal of Dermatology

Self Cite

View full text Add to dashboard Cite

burden do not reliably predict response to checkpoint inhibitor therapy. This is likely a multifactorial phenomenon comprised of varying host gene expression profiles, tumour molecular heterogeneity and unique tumour microenvironments. 6 There also exist differences in the anatomical domains of T lymphocytes, with skin-resident T cells being localized and active in the epidermis and high dermis compared with circulating T cells, which are present and functional in the peripheral blood, lymphatics and subdermal soft tissue. 7 Epidermal dysplasia and superficial cSCCs are likely able to evade recognition by circulating T cells, which are probably the group disinhibited by PD-1 inhibitor therapy. The early SCCs may essentially hide from the drug and the systemic immune response in the epidermis.As use of PD-1 inhibitors increases, we will have greater opportunity to observe this phenomenon of a possible epidermal-high dermal privileged tumour microenvironment. It will be useful to examine the impact of T-cell recruitment factors, both genetically determined host drug response and tumour specific, and functional differences in anatomical domains of T lymphocytes in the use of checkpoint inhibitors for keratinocyte carcinoma.

show abstract

Section: Subdomain Definition Themes Exemplar Quotesmentioning

confidence: 97%

mentioning

confidence: 99%

mentioning

confidence: 99%

mentioning

confidence: 99%

See 2 more Smart Citations

Qualitative analysis of the impact of atopic dermatitis on caregivers

Kim

Barta

Begolka

et al. 2022

British Journal of Dermatology

Self Cite

View full text Add to dashboard Cite

show abstract

Interventions for anxiety and depression in patients with atopic dermatitis: a systematic review and meta-analysis

Hartono,

Chatrath,

Aktas

et al. 2024

Sci Rep

Self Cite

View full text Add to dashboard Cite

Atopic dermatitis (AD) is a chronic inflammatory skin disease that is associated with anxiety and depression. Few studies have addressed interventions for symptoms of anxiety and depression in this population. To determine the efficacy of interventions for anxiety and depression in patients with AD. PubMed, MEDLINE, EMBASE, and PsycINFO were searched from inception to November 2023. English-language studies published in peer-reviewed journals evaluating the effect of interventions on anxiety and/or depression using validated assessment tools on patients with AD were included. Titles, abstracts, and articles were screened by at least two independent reviewers. Of 1410 references that resulted in the initial search, 17 studies were included. Fourteen of these studies are randomized controlled trials, while the other 3 studies are prospective controlled trials with pre and post-test designs. Data were extracted using a standardized extraction form, and the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines were followed. To accommodate trials with multiple interventions (each compared to a control group), we conducted a mixed-effects meta-analysis with the trial as a random effect. Prespecified outcomes were changes in symptoms of anxiety and depression in patients with AD as evaluated using standardized assessment tools. Of the 17 studies included in this systematic review, 7 pharmacological intervention studies with 4723 participants examining 5 different medications were included in a meta-analysis. Of these studies, only 1 study evaluated medications prescribed to treat anxiety and/or depression; the rest evaluated medications prescribed to treat AD. Meta-analysis of all the pharmacological interventions resulted in significant improvement in anxiety, depression, and combined anxiety-depression scale scores (standardized mean difference [95% CI]: − 0.29 [− 0.49 to − 0.09], − 0.27 [− 0.45 to − 0.08], − 0.27 [− 0.45 to − 0.08]) respectively. The 10 non-pharmacological studies with 2058 participants showed general improvement in anxiety but not depression. A meta-analysis of the non-pharmacological interventions was not conducted due to variable approaches and limited data. Pharmacological interventions designed to improve AD were found to improve anxiety and depression in patients with moderate-severe disease. More comprehensive studies on non-pharmacological and pharmacological interventions that primarily target anxiety and depression are needed.

show abstract